Arbutus to Repurchase Up to $230 Million in Shares via Modified 'Dutch Auction' Tender Offer

Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on infectious disease, has announced its intention to commence a modified "Dutch Auction" tender offer to repurchase up to US$230 million of its common shares. This strategic move reflects the company's commitment to returning capital to shareholders, offering a purchase price range of not less than US$5.00 and not more than US$5.75 per share in cash. The Offer is anticipated to begin on or about August 24, 2026, and, unless extended or terminated, expire on or about September 29, 2026.

The company's plan to fund this share repurchase program is primarily based on the cash proceeds received from a settlement agreement with Moderna, which was finalized in March 2026, with an initial payment received in July 2026. Arbutus received US$178.4 million as its share of the US$950 million non-contingent settlement payment made to Arbutus and its exclusive licensee, Genevant Sciences. Arbutus also holds approximately 16% of Genevant's outstanding common equity and expects to receive a material dividend from Genevant during the third quarter. Lindsay Androski, President and CEO of Arbutus, stated that the company intends to return the financial proceeds from this litigation win to the shareholders who have supported the company throughout this prolonged process.

A modified "Dutch Auction" tender offer allows shareholders to indicate the price within a specified range at which they are willing to sell their shares. Arbutus expects to commence the offer promptly following the receipt of certain exemptive relief under applicable securities laws in Canada and the United States, for which it has applied. J.P. Morgan Securities LLC will serve as the Dealer-Manager for the offer, with Georgeson LLC acting as the Information Agent and TSX Trust Company as the Depositary.

The initial market reaction to this announcement was mixed. Following the news, Arbutus shares (ABUS) declined by 4.19%, indicating a moderate negative market response. However, a peak intra-day movement of +7.6% was also observed. The company's current market capitalization stands at US$904.16 million. While share repurchase programs typically provide a supportive effect on stock prices, in Arbutus's specific case, this move highlights the company's financial strength and strategic steps for the future.

The settlement with Moderna marked a significant milestone in Arbutus's legal battles concerning its lipid nanoparticle (LNP) technology patents. The company emphasizes that this technology has opened the doors to an entirely new world of therapeutic treatments using nucleic acids. Arbutus, alongside its exclusive licensee Genevant, also affirmed its commitment to vigorously enforce its patent rights against other infringers, including Pfizer and BioNTech. The company remains focused on developing clinical-stage treatments for chronic hepatitis B infection, including imdusiran (AB-729) and an oral PD-L1 inhibitor (AB-101).

Market analysts suggest that Arbutus's determination to protect its patent portfolio and return proceeds from the Moderna settlement to shareholders could bolster the company's long-term value. However, the commencement of the tender offer is subject to regulatory approvals, and potential future contingent payments from the Moderna agreement are tied to specific outcomes, which will be closely monitored by investors. The company's continued R&D activities in the biopharmaceutical sector also remain crucial for its growth potential.